Acer Therapeutics Investigational Trial For Celiprolol

The DiSCOVER Trial

Decentralized Study of Celiprolol on vEDS-related Event Reduction

Acer Therapeutics plans to conduct a clinical trial in the U.S. to evaluate the efficacy of a medicine known as celiprolol for the treatment of vascular Ehlers-Danlos Syndrome (vEDS). The study is being planned to evaluate males and females who have a confirmed diagnosis of vEDS by a COL3A1 mutation verified by genetic testing.

As planning for the trial progresses, we are actively looking for potential participants with a confirmed diagnosis of vEDS who are interested in participating in this investigational trial. As with any clinical study, participation will be subject to a number of inclusion and exclusion criteria.

Celiprolol is an investigational product and the safety and efficacy has not been established. There is no guarantee that celiprolol will receive health authority approval or become commercially available for vEDS.

vEDS as confirmed with a
positive COL3A1 mutation

U.S.A. Resident

Interested in learning more?

Complete the form below.

Have you or someone you care for been diagnosed with vascular Ehlers-Danlos Syndrome?(Required)

Yes, I am diagnosed with vascular Ehlers-Danlos Syndrome (COL3A1+ confirmed)

Yes, I am diagnosed with vascular Ehlers-Danlos Syndrome (COL3A1 status unknown)

No, but I am a family member/caregiver for someone that has been diagnosed with vascular Ehlers-Danlos Syndrome

No, but I am a clinician who treats patients with vascular Ehlers-Danlos Syndrome

No, but I am interested in the study

Is the person with vEDS currently living in the United States?

Yes

N/A

Your Name(Required)

Email(Required)

Phone(Required)

Address(Required)

Yes, please contact me(Required)

I agree for authorized contracted service providers, clinical trial sites, and representatives of Acer Therapeutics to contact me in relation to vascular Ehlers-Danlos Syndrome investigational trials and related activities.